Basel, 04 May 2017
Save the date: Roche Analyst Event at ISTH 2017
Monday, 10 July 2017, 6:30pm CEST
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017.
During the briefing, Roche will discuss new data for emicizumab (ACE910) in hemophilia A:
HAVEN1 - phase 3 study of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors
HAVEN2 - phase 3 study of emicizumab (ACE910) in pediatric persons with hemophilia A with inhibitors
Hotel Berlin, Berlin
Monday, 10 July 2017 @ 6:30pm CEST
The briefing will be followed by a buffet reception.
An invitation with the detailed programme and registration form will follow shortly.
Head of Investor Relations
Investor Relations Officer